-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Psychedelics Companies Explore & Protect Their Findings, This Firm Is Doing That In 16 Countries
Psychedelics Companies Explore & Protect Their Findings, This Firm Is Doing That In 16 Countries
Psychedelics R&D company Mindset Pharma (OTCQB:MSSTF) has filed no less than 16 national applications, including countries within the main South East Asian markets, for one of its key families of next-generation psychedelic compounds.
The company recently announced the creation of three additional families (6, 7 and 8) of non-tryptamine psychedelic compounds. The new patent applications include drug candidates belonging to "Family 1," which is composed of second-generation psilocybin analogs.
According to Mindset, Family 1 compounds hold the potential of improving in size, safety and manufacturing when compared to psilocin and psilocybin. The group includes the first-elected clinical and most advanced drug candidate MSP-1014, a psilocybin-like entity that has demonstrated safety, improved efficacy and reduced potential side effects compared to first-generation psilocybin in preclinical studies and is set to be tested in clinical trials in 2023.
Furthermore, the company's IP portfolio strategy has made it recently file a provisional application with the US Patent and Trademark Office (USPTO) for the application of a novel chemical structural strategy to Family 1.
Mindset CEO James Lanthier explained: "Mindset is applying state of the art innovative medicinal chemistry to expand our rich pipeline of optimized psychedelic medications with improved overall efficacy and reduced toxicity profiles and we will continue to protect our compound pipeline and ensure that we provide the most effective options for patients with neurological and psychiatric disorders."
Mindset additionally announced grant options for up to 200,000 common shares at $0.55 each and expiring on September 6, 2023.
Photo courtesy of Pexels.
Psychedelics R&D company Mindset Pharma (OTCQB:MSSTF) has filed no less than 16 national applications, including countries within the main South East Asian markets, for one of its key families of next-generation psychedelic compounds.
迷幻剂研发公司思维定势制药(OTCQB:MSSTF)已提交不少于16个国家的申请,包括东南亚主要市场,用于其关键的下一代迷幻化合物家族之一。
The company recently announced the creation of three additional families (6, 7 and 8) of non-tryptamine psychedelic compounds. The new patent applications include drug candidates belonging to "Family 1," which is composed of second-generation psilocybin analogs.
该公司最近宣布再创建三个非色胺迷幻化合物家族(6、7和8)。新的专利申请包括毒品候选人属于“家庭1”,它由第二代裸盖菇素类似物组成。
According to Mindset, Family 1 compounds hold the potential of improving in size, safety and manufacturing when compared to psilocin and psilocybin. The group includes the first-elected clinical and most advanced drug candidate MSP-1014, a psilocybin-like entity that has demonstrated safety, improved efficacy and reduced potential side effects compared to first-generation psilocybin in preclinical studies and is set to be tested in clinical trials in 2023.
根据心态,家族1化合物具有潜在的在尺寸、安全性和制造方面的改进与裸盖菇素和裸盖菇素相比。该小组包括首次当选的临床和最先进的候选药物MSP-1014,这是一种类似裸盖菇素的实体,在临床前研究中已经证明了与第一代裸盖菇素相比,它的安全性、有效性和减少了潜在的副作用,并将于2023年在临床试验中进行测试。
Furthermore, the company's IP portfolio strategy has made it recently file a provisional application with the US Patent and Trademark Office (USPTO) for the application of a novel chemical structural strategy to Family 1.
此外,该公司的知识产权组合战略最近向美国专利商标局(USPTO)提交了一份临时申请,将一种新的化学结构策略应用于家族1。
Mindset CEO James Lanthier explained: "Mindset is applying state of the art innovative medicinal chemistry to expand our rich pipeline of optimized psychedelic medications with improved overall efficacy and reduced toxicity profiles and we will continue to protect our compound pipeline and ensure that we provide the most effective options for patients with neurological and psychiatric disorders."
思维定势首席执行官詹姆斯·兰蒂耶解释说:“Mindset正在应用最先进的创新药物化学来扩展我们丰富的优化迷幻药物流水线,以提高整体疗效和降低毒性。我们将继续保护我们的复合体管道并确保我们为神经和精神障碍患者提供最有效的选择。“
Mindset additionally announced grant options for up to 200,000 common shares at $0.55 each and expiring on September 6, 2023.
心态另行公布授予选项最多20万股普通股,每股0.55美元,2023年9月6日到期。
Photo courtesy of Pexels.
照片由Pexels提供。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧